RNA-based therapies

With the first wave of FDA-approved siRNA drugs under their belt, companies are racing to expand into new tissues and indications.

Acquisition brings Avidity’s RNA delivery platform and late-stage neuromuscular programs under Novartis, expanding its capabilities in developing precision genetic medicines.

By combining synthetic biology, computational design, and novel RNA formats, these therapies adapt in real time to disease signals, enabling previously impossible treatments.

An oligonucleotide transport vehicle could transform neurological disease treatment by enhancing drug delivery across the blood-brain barrier.

The durability and capacity to boost protein expression of circular RNA makes it a promising candidate for next-generation vaccines and gene therapies.